Analyte sensing biointerface
First Claim
Patent Images
1. An implantable continuous glucose sensor system, comprising:
- a transcutaneous sensor comprising a working electrode configured to measure a signal indicative of a glucose concentration in an interstitial fluid;
a membrane disposed on the working electrode, wherein the membrane comprises a biointerface, wherein the biointerface comprises;
a first bioactive agent, wherein the first bioactive agent is configured to reduce effects from inflammation associated with the working electrode, wherein the first bioactive agent is configured to be released during a first time period; and
a second bioactive agent, wherein the second bioactive agent is different from the first bioactive agent, wherein the second bioactive agent is configured to reduce effects from a continual decline in sensor sensitivity, wherein the second bioactive agent is configured to be released during a second time period, wherein the first time period is different from the second time period, wherein the second time period ends later than the first time period; and
electronics electrically coupled to the working electrode.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed herein is an analyte sensing biointerface that comprises a sensing electrode incorporated within a non-conductive matrix comprising a plurality of passageways extending through the matrix to the sensing electrode. Also disclosed herein are methods of manufacturing a sensing biointerface and methods of detecting an analyte within tissue of a host using an analyte sensing biointerface.
311 Citations
4 Claims
-
1. An implantable continuous glucose sensor system, comprising:
-
a transcutaneous sensor comprising a working electrode configured to measure a signal indicative of a glucose concentration in an interstitial fluid; a membrane disposed on the working electrode, wherein the membrane comprises a biointerface, wherein the biointerface comprises; a first bioactive agent, wherein the first bioactive agent is configured to reduce effects from inflammation associated with the working electrode, wherein the first bioactive agent is configured to be released during a first time period; and a second bioactive agent, wherein the second bioactive agent is different from the first bioactive agent, wherein the second bioactive agent is configured to reduce effects from a continual decline in sensor sensitivity, wherein the second bioactive agent is configured to be released during a second time period, wherein the first time period is different from the second time period, wherein the second time period ends later than the first time period; and electronics electrically coupled to the working electrode. - View Dependent Claims (2, 3, 4)
-
Specification